The business ideas were wide-ranging. Eight teams presented innovative solutions to challenges in the laboratory/healthcare sector as well as new therapy options for hard-to-treat cancers and respiratory diseases.
In advance, BioM prepared the founders in a training one week prior to the Pitch Day. With the BioM team, the start-up teams and an external expert offered each other feedback in a collaborative workshop format. The aim was to present the business model and scientific data succinctly. Equipped with new feedback, the teams went home and optimized their pitches. As a result, the teams were well prepared for the vetting questions of the invited investors following their pitches.
Benjamin Winkeljann from RNhale explained: “When you’re practicing your pitch on your own, you’re creating for yourself. But when you’re in a room with people with different background and experiences, you’re introduced to new perspectives that can really elevate your pitch.” Rnhale aims to develop a platform technology for formulating RNA-loaded lipid nanoparticles (LNPs) as an inhalable dry powder.
The Dymium team was delighted to have the opportunity to present their idea to an audience eager to invest. “The BioM BioAngels event is a great opportunity to meet investors when you’re actively fundraising," said Florian Ebel. The company, which was awarded the BioRegions Innovation Award in 2021, has developed a technology that makes it possible to reliably remove even the smallest fragments of kidney stones.
The BioM BioAngels Pitch event was once again very well received by investors.
Paul Sunzenauer of OCCIDENT offered his perspective: "We find that BioM is a quality source for deals. As a deeptech investor, it is difficult to find unique and promising early-stage prospects. It’s necessary for us to have a relationship with BioM to find these companies."
As part of its diverse start-up support program, BioM helps bioentrepreneurs connect with potential investors in the biomedical field through matchmaking events.
The teams who presented at the BioAngels Pitch Day 2024 and their ideas:
Dymium – Reducing the global recurrence of kidney stones.
The Dymium Magnetic Retrieval System revolutionizes kidney stone surgery, minimizing recurrence risk for patients and delivering highest quality treatment in shorter operation time.
Elexion Medical – Fight care shortage with digitization of patient monitoring.
Elexion Medical helps fight the care shortage and improve patient outcome in hospitals and nursing homes by automated monitoring of patients’ fluid lines with SaaS, AI and enabling IoT devices.
RNhale – The Next Generation of Inhalable RNA Therapeutics.
RNhale is a spin-off originating from the LMU Munich, aiming to revolutionize the pharmaceutical landscape by developing a unique platform technology for formulating RNA-loaded lipid nanoparticles (LNPs) as an inhalable dry powder. This disruptive approach synergizes technological and pharmaceutical strategies to create a novel therapeutic formulation with significant advantages over common LNP-RNA delivery methods.
Deep Piction – Intelligence in Medicine.
Deep Piction’s unique technology platform enables it to provide experimental and AI services to assess drug effects in large 3D samples and to become a major player in AI-driven drug development.
UniteLabs – The Lab 4.0 Platform.
UniteLabs is an integration platform for lab automation that connects hard- & software across vendor barriers to digitalise life science R&D.
XO Life – Provide every patient with digital product and treatment companion.
XO Life aims to build the biggest and best global patient platform for high quality patient knowledge, real world patient data, patient exchange and support in everyday care. Today, patients usually turn to Dr. Google, Facebook, Insta and Co. for research and exchange because there is no reasonable highly attractive patient platform.
PRAMOMOLECULAR – Silencing Cancer.
PRAMOMOLECULAR is silencing cancer proteins: no cancer protein – no tumour growth.
AATec Medical – New accessible and affordable therapeutics for globally increasing respiratory diseases.
AATec Medical is a new biotech Munich-based startup developing new therapies for inflammatory diseases and viral infections of the airways. Target indications are acute respiratory distress syndrome (ARDS), respiratory viral infections and severe allergic asthma.
For 25 years, BioM has been the networking organization for the biotechnology industry in Munich and Bavaria, acting on behalf of the Bavarian Ministry of Economic Affairs.
BioM supports the Bavarian biotechnology and pharmaceutical industry with an extensive network in establishing new business contacts. The cluster management offers interested parties from Germany and abroad central access and a wide range of information about the industry. Especially for prospective company founders, BioM offers comprehensive advice and specialized coaching, training and mentoring programs.
In addition, BioM will open its incubator MAxL (Munich Accelerator Life Sciences & Medicine) for pre-seed projects and early-stage start-ups in the biotech and healthtech sector. Since 2011, BioM has been coordinating the m4 Award pre-seed competition in the field of biomedicine, which is funded by the Bavarian Ministry of Economic Affairs with a total of 2.5 million euros. In total, BioM has supported over 250 start-ups. BioM also organizes a wide range of training courses, events and network meetings.
More information: www.bio-m.org
BioM Biotech Cluster Development GmbH
Am Klopferspitz 19a
82152 Martinsried
Telefon: +49 (89) 899679-0
Telefax: +49 (89) 899679-79
http://www.bio-m.org
Marketing & Communications Lead
Telefon: +49 (89) 899679-15
E-Mail: klingner@bio-m.org
PR & Social Media Manager
Telefon: +49 (0) 89 / 89 96 79-39
E-Mail: proll@bio-m.org
